Harrow, Inc. (NASDAQ: HROW)

Harrow, Inc., represented by the stock symbol HROW, is a prominent player in the eyecare pharmaceutical industry, specializing in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. The company boasts ownership of commercial rights to a substantial portfolio of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name.

Harrow's primary business activities revolve around the production and distribution of branded ophthalmic pharmaceutical products and the operation of ImprimisRx, an ophthalmology-focused pharmaceutical compounding business. These activities are carried out in the United States, with the company's headquarters located in New York.

The company's revenue is generated through the sale of its branded ophthalmic pharmaceutical products, which include IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, and NEVANAC, among others. ImprimisRx, Harrow's compounding business, offers customized medications to meet the clinical needs of patients.

Within the industry, Harrow maintains a competitive position against branded and generic drug companies, outsourcing facilities, and compounding pharmacies. The company's competitive advantages are attributed to its comprehensive portfolio of branded ophthalmic pharmaceutical products, its ability to offer customized medications through ImprimisRx, and its non-controlling equity interest in Melt Pharmaceuticals, Inc.

Harrow's customer base comprises ophthalmologists, optometrists, and other healthcare professionals who prescribe and dispense its products to patients. The company's products are used to treat a variety of eye conditions, such as dry eye disease, cataracts, and age-related macular degeneration.

Harrow's brand names and trade names include IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, and ImprimisRx. These products are designed to address various ophthalmic disorders and provide customized solutions for patients.